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Abstract
Background: Prion diseases are fatal neurodegenerative disorders characterized by misfolding and aggregation of the
normal prion protein PrP
C. Little is known about the details of the structural rearrangement of physiological PrP
C into a still-
elusive disease-associated conformation termed PrP
Sc. Increasing evidence suggests that the amino-terminal octapeptide
sequences of PrP (huPrP, residues 59–89), though not essential, play a role in modulating prion replication and disease
presentation.
Methodology/Principal Findings: Here, we report that trypsin digestion of PrP
Sc from variant and sporadic human CJD
results in a disease-specific trypsin-resistant PrP
Sc fragment including amino acids ,49–231, thus preserving important
epitopes such as the octapeptide domain for biochemical examination. Our immunodetection analyses reveal that several
epitopes buried in this region of PrP
Sc are exposed in PrP
C.
Conclusions/Significance: We conclude that the octapeptide region undergoes a previously unrecognized conformational
transition in the formation of PrP
Sc. This phenomenon may be relevant to the mechanism by which the amino terminus of
PrP
C participates in PrP
Sc conversion, and may also be exploited for diagnostic purposes.
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Introduction
Prion diseases are fatal neurodegenerative disorders character-
ized by dementia, motor dysfunction, and spongiform degenera-
tion of the brain [1]. Propagation of the infectious prion particle is
attributable to a conformational conversion of the widely
expressed normal prion protein PrP
C into an abnormal, infectious
conformation termed PrP
Sc. PrP
Sc, unlike the physiological protein
PrP
C, exists predominantly in an aggregated form and is partially
resistant to protease digestion [2]. Digestion with Proteinase K
(PK) leaves behind a core particle termed PrP
res (for resistant PrP)
or PrP
27–30 (for 27–30 kDa PK-resistant fragments) that consists of
the carboxy-terminal two-thirds of the protein. Consequently, the
PK-labile amino-terminus has been suggested to be solvent-
accessible and largely unstructured in the context of PrP
Sc as it is
in PrP
C [3,4]. Furthermore, because PrP
27–30 remains infectious
and because of the scarcity of tools to isolate full-length PrP
Sc, the
amino-terminus has remained relatively unexamined in the
context of aggregated PrP.
The amino-terminal tail of PrP is known to contain an array of
fivealmostidenticaloctapeptidesequences,alsotermedoctarepeats,
that has been reported to play a role in copper binding and
homeostasis [5], as well as in protection from oxidative stress
(reviewed in [6]). Importantly, mutations that result in expansion of
the octarepeats have been linked to familial Creutzfeldt-Jakob
Disease (CJD). Documented cases of familial CJD report insertions
of 2–9 octapeptide sequences [7–9], whose impact are recapitulated
in transgenic mouse models [10]. Likewise, transgenic mice
expressing PrP that lack all five octapeptide sequences appear to
be impaired in propagating PrP
Sc, as these mice have longer
incubation periods before they become symptomatic, lower prion
titers, reduced amounts of PrP
res, and no observable histopathology
[11,12]. In vitro studies also support a role of the octarepeats in PrP
Sc
replication as octapeptide insertions or deletions affect the rate and
propensity of oligomerizationforrecombinant PrP [13,14]. As such,
understanding the function of the amino-terminal portion of PrP is
critical for understanding propagation of prion diseases.
Despite the importance of the amino-terminus, previous prion
research has primarily focused on PK-treated PrP
Sc, partly
because of the difficulties associated with separating PrP
Sc from
PrP
C in infectious samples. Other biochemical means of protein
enrichment such as antibody immunoprecipitation are largely
ineffective at separating PrP
C from PrP
Sc due to their sequence
identity. PK digestion has been employed to circumvent this issue,
but at the cost of removing amino-terminal sequences and
decreasing yields of PrP
Sc and scrapie-associated infectivity [15].
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trypsin, rather than PK, to distinguish PrP
C from PrP
Sc. We found
that indeed trypsin cleavage significantly digested PrP
C, but
retained the majority of PrP
Sc, thus providing a means to separate
the isoforms while maintaining the octarepeat sequence. Using this
technique, we found the octarepeat sequence had multiple
epitopes exposed in PrP
C but not PrP
Sc, suggesting that there is
a conformational transition in this region during the conversion of
PrP
C to PrP
Sc. Given the putative role of the octarepeat in
infectivity, this novel structural change may provide clues to the
mechanism of PrP
Sc replication.
Results
Trypsin Digests PrP
C While Preserving PrP
Sc
To characterize the physicochemical properties of the PrP
Sc
octarepeat region, we needed to preserve amino-terminal
sequences while still removing PrP
C from CJD samples. Given
the nonspecific nature of PK digestion, we chose to digest the
samples with a more specific enzyme, trypsin, which cleaves only
on the C-terminal side of lysine and arginine residues. The
predicted tryptic map for the human PrP sequence shows that the
majority of cleavage sites are within the PK-resistant core (Fig. 1A,
Figure 1. Trypsin significantly digests PrP
C while preserving almost full-length PrP
Sc. A. Schematic of the full-length mature PrP sequence,
PK-digested PrP
Sc and PrP
C, and trypsin-digested PrP
Sc and PrP
C. Trypsin cleavage sites are indicated by triangles, with gray triangles lying within the
PK-resistant core and red triangles indicating expected cleavage sites. B. 50 mg/ml trypsin or PK was incubated with normal (ctrl), vCJD MM (codon
129 polymorphism), sCJD MM, and sCJD MV BHs. Samples were separated by SDS-PAGE and immunoblotted with POM2, 3F4, and POM17 antibodies.
An actin immunoblot was performed as a proteolysis control. C. Trypsin removes the octarepeats and 3F4 epitope of PrP
C, but not helix one. Normal
and vCJD BHs were digested with 0, 25, 50, 75 or 100 mg/ml trypsin and then analyzed by immunoblotting with POM2, 3F4, and POM1 antibodies.
doi:10.1371/journal.pone.0009316.g001
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residues 23–49 of the mature PrP sequence (Fig. 1A, red triangles)
and no sites within the octarepeat region (residues 51–91). To
confirm this prediction, we digested brain homogenates (BHs)
from several CJD strains in parallel with PK as a control.
Immunoblot analysis of the digests indicated that trypsin-resistant
PrP fragments (expected to be ,49–231) had higher mass than
PK-resistant fragments (,90–231) with a substantial fraction of
molecules preserved (Fig. 1B, 3F4 antibody recognizing residues
,109–112 and POM17 antibody recognizing residues ,144–
155). Mass spectrometry of human recombinant PrP23–231
validated that trypsin could cleave at all the sites predicted by
the PrP sequence, thus confirming that the tryptic sites were
conformationally protected in PrP
Sc (data not shown). Further
examination revealed that digestion with trypsin but not PK
preserved the PrP octapeptide repeats recognized by the POM2
antibody (Fig. 1B, POM2 antibody recognizing residues ,59–89).
Importantly, preservation of this region significantly enhances PrP
detection (Fig. S1).
By contrast, PrP
C was digested by both proteases, and was no
longer detected by POM2 and 3F4 (Fig. 1B and 1C, Normal).
However, when we immunoblotted the digests with POM17 or
POM1 antibody (recognizing helix one, residues ,144–155), we
observed a trypsin-resistant fragment of ,25 kDa. Given that the
structure of PrP
C is composed of a globular domain (,122–231)
following an unstructured amino-terminus [19,20], the 25 kDa
trypsin-resistant fragment likely included the globular domain as it
was the appropriate molecular weight and detected by POM1 and
POM17 but not POM2 or 3F4 antibodies (Fig. 1B, 1C).
Interestingly, this would suggest that the globular domain is
tightly folded and that the tryptic sites within the POM17/POM1
epitope (R148 and R151) are not accessible for cleavage, contrary
to how they appear in the solution structure [20]. To better
understand the resistance of this domain to digestion, we digested
both normal and variant CJD (vCJD) BHs with increasing
amounts of trypsin (Fig. 1C). The amino-terminal sequences of
PrP
C were extremely labile as no PrP was detected by either
POM2 or 3F4 at any of the trypsin concentrations tested, but a
PrP
C 25 kDa fragment and PrP
Sc from vCJD BH were resistant to
digestion. A survey of other non-CJD BHs confirmed the presence
of a 25 kDa PrP
C tryptic fragment, indicating that the fragment
was not unique to that sample (data not shown). However, as most
of our studies of PrP
Sc utilized 3F4 and POM2 epitopes, PrP
C
trypsin-resistant fragments did not impact our analysis.
Measuring the Stability of PrP
Sc Epitopes Against Trypsin
Digestion
To better quantitate the sensitivities of specific PrP epitopes to
PK or trypsin cleavage, we measured protease-resistant epitopes
by direct ELISA (Fig. 2A). Normal (129 MM), vCJD (129 MM),
and sporadic CJD (sCJD) (129 MM and 129MV) BHs were
digested with increasing amounts of trypsin or PK, followed by
centrifugation. PrP in the pellets was denatured, coated to
microtiter plates, and detected by direct ELISA. The centrifuga-
tion protocol efficiently separated PrP
C from PrP
Sc, with the small
amount of residual PrP
C efficiently removed via proteolysis with
1 mg/ml protease (see Fig. 2B, compare PrP
C from normal BH
and PrP
C+PrP
Sc from vCJD digested BH). To directly compare
the amount of PrP
Sc preserved by each protease, we subtracted the
PrP
C-derived signal detected in normal BH from each of the
infectious samples (Fig. 2C, CJD - Normal).
As expected, we found significant differences in the exposure of
PrP
Sc epitopes to trypsin versus PK digestion. Equal amounts of
the core particle were preserved with either protease, as shown by
3F4 reactivity (Fig. 2C), whereas the octarepeat region was
preserved only for trypsin digested PrP
Sc as shown by POM2
reactivity. The octarepeats were excised only at high concentra-
tions of trypsin but rapidly disappeared with PK digestion (Fig. 2C,
POM2). POM17 detection of the PrP
Sc core particle was
consistent with our results via 3F4 detection and confirmed that
the vast majority of helix one was resistant to trypsin digestion
(Fig. 2C, POM17). On the other hand, POM17-detected PrP
decreased with increasing PK despite the PK-resistance of the
PrP
Sc core particle, in agreement with previous reports that high
concentrations of PK will also digest the PK-resistant core
(reviewed in [21]). Because PK is a nonspecific protease, PK
may cleave at certain sites resulting in conformational destabili-
zation of the PrP
Sc core particle and further proteolysis. It is likely
that trypsin does not recognize these sites. Therefore, sequences
such as the octarepeat and helix one regions are uniquely
preserved in trypsin digestion, making trypsin an ideal tool for
analysis of PrP
Sc.
The Octarepeat Region Undergoes a PrP
Sc-Specific
Conformational Change
Despite extensive studies of PrP variants bearing mutations of
the octarepeat region, understanding of the properties of this
domain remain unclear. Preservation of the region by digestion
with trypsin allowed us to study its structure by an epitope
protection approach. Digested PrP
Sc from CJD BHs was coated
directly to ELISA plates and probed with various antibodies to
identify conformationally hidden epitopes. The stability of these
conformations could be assessed by treatment with increasing
amounts of denaturant (guanidine hydrochloride, GdnHCl) and
looking for recovery of immunoreactivity. This ELISA-based
approach allowed us to survey several different strains in both a
high throughput and quantitative manner. Importantly, maximal
antibody binding was observed for PrP
C at all concentrations of
GdnHCl surveyed, demonstrating that the epitopes examined are
accessible in the native conformation of PrP
C and that guanidine
treatment of the passively-coated material did not strip PrP from
the plate (Fig. 3A).
We next examined PrP
Sc from CJD brain homogenates. The
high endogenous levels of PrP
C were digested away by PK or
trypsin treatment and the immunoreactivity of PrP
Sc was tested
after treatment with denaturant. Increasing amounts of GdnHCl
yielded dramatic increases in 3F4 reactivity for all strains (Fig. 3B),
consistent with previous reports that this region undergoes a major
conformational change upon conversion of PrP
C to PrP
Sc [22–24].
Next, we examined the conformational stability of the
octarepeat region which has been previously presumed to be
unstructured in PrP
Sc. Consistent with this view, significant POM2
immunoreactivity was observed even under native PrP
Sc condi-
tions after trypsin digestion (Fig. 3B, POM2). However, when
PrP
Sc was unfolded with GdnHCl there was a ,5–10 fold increase
in POM2 immunoreactivity, suggesting that this region indeed is
buried in PrP
Sc and undergoes a conformational change upon
conversion of PrP
C to PrP
Sc. As expected, significantly different
levels of PrP
Sc were detected after PK digestion. No POM2 signal
was observed for PK-digested PrP
Sc from vCJD BH, in agreement
with the complete digestion of the octapeptides in this strain
[25,26]. Many, if not all, sCJD isolates are reported to contain
both type 1 and 2 PrP
Sc [27,28], thus retaining a mixture of PrP
Sc
protease-resistant fragments with some containing a single
octapeptide (type 1) after PK digestion [25], that could be
detected by POM2 (Fig. 3B, POM2 detection of sCJD).
Interestingly, PK-resistant PrP containing a single octapeptide
had a similar conformational stability as the trypsin-digested PrP
PrP
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trypsin and PK).
We further confirmed these findings by immunoprecipitation
studies for the vCJD sample, which appeared to contain the most
homogeneous PrP
Sc by quantitative ELISA assays (Fig. 3C).
Normal and vCJD BHs were digested, PrP
Sc was centrifuged
(Fig. 3C, lanes 1–6, input), and PrP
Sc pellets were treated with or
without denaturant, and immunoprecipitated with antibodies
recognizing the various epitopes of interest. The immunoprecip-
itates were then examined by POM1 immunoblot (Fig. 3C, lanes
13–36). As expected, antibodies with epitopes buried within the
protease-resistant core (3F4 and POM17) immunoprecipitated
denatured but not native PrP
Sc relative to negative controls
(Fig. 3C, POM19 immunoprecipitations; POM19 does not
recognize human PrP).
Next, we examined the ability of POM2 to bind the octapeptide
repeats. Consistent with our ELISA studies (Fig. 3B), no PrP was
immunoprecipitated from PK-digested PrP
Sc (Fig. 3C). On the
other hand, PrP
Sc from trypsin-digested BHs could be immuno-
precipitated in agreement with the finding that one or more of the
octapeptides are accessible (Fig. 3C). Similar to what we observed
by ELISA, a larger proportion of PrP could be immunoprecip-
itated via POM2 antibody when PrP
Sc was first denatured with
guanidine treatment. Thus, the increased yield of POM2
immunoprecipitation upon denaturation of PrP
Sc supports the
idea that the octapeptide domain undergoes a structural transition
upon formation of PrP
Sc.
Discussion
A Structural Change in the Octarepeat Region of PrP
Sc
and Prion Propagation
Despite extensive debate, the importance of the PrP octapeptide
sequences in PrP
Sc pathophysiology remains unclear. Initially, the
region was thought to be unnecessary since PK-digested PrP
Sc
from tissue samples still proved to be infectious. However,
emerging evidence suggests that the octapeptide sequences may
play a role in propagating prions. For instance, insertion of 1–9
octapeptides into the PrP sequence has been linked to several cases
of familial CJD [9,29,30]. The effects of this octarepeat expansion
Figure 2. Sensitivity of PrP
Sc epitopes to trypsin digestion. A. Schematic of trypsin cleavage map of PrP with the indicated locations of
antibody epitopes. B&C .Normal and CJD BHs were digested with increasing amounts of trypsin (filled symbols) or PK (open symbols). Digests were
centrifuged, pellets were denatured, and PrP was detected by direct ELISA. B. Detection of digested normal (triangles) and vCJD (circles) samples is
shown in relative light units (RLU). C. Detection of vCJD MM, sCJD MM, and sCJD MV samples digested with trypsin or PK are shown in a normalized
format by subtracting away the signal derived from normal samples (CJD – Normal, RLU). Error bars in B indicate the standard deviation measured
from samples prepared in triplicate. Similar errors were measured for CJD samples but are not shown for normalized data in C.
doi:10.1371/journal.pone.0009316.g002
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octapeptide sequences who demonstrate clinical (ataxia), histo-
pathological (neuronal apoptosis and accumulation of aggregated
PrP), and biochemical (protease-resistant PrP) hallmarks of prion
disease [10]. While transgenic mice expressing PrP lacking the
octapeptide sequences remain susceptible to scrapie infection,
these mice appear to be impaired in PrP
Sc propagation as they
exhibit longer incubation times, no histopathology, and signifi-
cantly reduced prion titers and protease-resistant PrP [11]. In vitro
aggregation studies also support involvement of the octarepeat
region in PrP oligomerization. For instance, expansion of the
octarepeats increased the rate of oligomerization for recombinant
PrP [13], while deletion of the octarepeats resulted in reduced
oligomerization [14]. These data together demonstrate that the
octarepeat region is not required for disease progression, but that it
may facilitate prion propagation and/or pathogenesis.
Given that the octarepeats are largely PK-sensitive, it has been
presumed that the region contributes little structure to PrP
Sc.
Here, by using trypsin digestion of PrP
Sc to preserve most of the
PrP sequence (estimated ,49–231) we have revealed that there is
indeed a structural transition in the octarepeat region in the
conversion of PrP
C to PrP
Sc. The structural change we measured
upon denaturation (5–10 fold increase in detected PrP) mimics the
structural changes observed within the PK-resistant core (Fig. 3B,
3F4) [22,24,31].
Several possibilities exist for how the octarepeat region may
affect prion disease pathology. First, the octapeptide sequences
may modulate the toxicity of PrP
Sc. Currently, the loss of
infectivity resulting from PK digestion is largely attributed to the
digestion of some proportion of PrP
Sc (,90–231) [15,17], but it is
possible that infectivity is lost with the PK-labile amino-terminus
as well. Second, the octapeptide sequence may be prone to self-
Figure 3. Epitope presentation of native and chemically denatured PrP
Sc. A. PrP
C from normal BH was coated to ELISA plates, denatured
with 0–5M GdnHCl, and detected by direct ELISA with the indicated antibodies. Results are shown in relative light units (RLU). B. Normal and CJD BHs
treated with 50 mg/ml trypsin (filled symbols) or PK (open symbols) were centrifuged. Pellets were then coated to ELISA plates in duplicate, treated
with 0–5 M GdnHCl, and PrP was detected by direct ELISA. The data shown is normalized by subtracting the signal derived from normal samples from
that of the CJD samples (CJD – Normal, RLU). All plots are shown in log scale. C. PrP from vCJD or Normal BHs was digested and pelleted as in B,
treated with 0 or 5 M GdnHCl, renatured, and immunoprecipitated with either a negative control (POM19) or with POM2, 3F4 or POM17 antibodies.
Immunoprecipitations and 40% of the total immunoprecipitation input was immunoblotted with POM1 antibody. Error bars in A indicate the
standard deviation measured from samples prepare in duplicate. Similar errors were measured for CJD samples in B with all coefficients of deviations
less than 15% for signals above background. Errors are not shown for normalized data.
doi:10.1371/journal.pone.0009316.g003
PrP
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C, a process that,
even if not strictly required for generation of prions, could
accelerate conversion to PrP
Sc. In vitro binding and aggregation
studies with octapeptide multimers of varying lengths support this
theory [32,33]. Our finding that the octarepeats undergo a
structural transition in the conversion of PrP
C to PrP
Sc open up
another possibility that structural components of the octarepeat
region, either alone or in conjunction with the primary sequence,
may enhance the ability of PrP
Sc to propagate.
PrP
Sc Isolation by Trypsin Digestion
We have developed a novel method of purifying PrP
Sc from
infectious samples that preserves the majority of the PrP sequence.
Future studies comparing the infectious titers of PK- and trypsin-
digested samples would allow the contribution of the octarepeats
to infectivity to be directly measured. This method could also be
used as an enhanced diagnostic tool. Our sandwich ELISA was
found to yield superior detection by preserving multiple POM2
epitopes. Because its cognate epitope is repeated on PrP, POM2
can dock to PrP through multiple interactions, yielding extremely
high avidities in the femtomolar range [18]. This peculiarity
renders trypsinization, followed by ELISA, one of the most
sensitive methods for detecting authentic PrP
Sc (Fig. S1, Methods
and Results S1). The sensitivity gained by additional POM2
epitopes is also apparent in the amount of PrP captured by POM2
immunoprecipitation (Fig. 3C). Chemical denaturation of PrP
exposed additional epitopes, enhancing the amount of PrP
captured several fold over a single POM2, 3F4 or POM17
epitope. In addition, since PK-digested PrP
Sc has a high
propensity to fibrillize in solution [34], preservation of full-length
PrP
Sc may enhance the solubility of the aggregate, making it more
amenable to structural studies – e.g. by solid-state nuclear
magnetic resonance spectroscopy which necessitates large amounts
of highly purified analytes. Moving forward, we now have the
ability to purify PrP
Sc that closely approaches unmodified,
physiological aggregates. This new tool may help to dissect the
role of the octarepeat region in prion disease.
Materials and Methods
Tissue Samples
CJD brain homogenates (BHs) were acquired from the NIBSC
CJD Resource Centre and correspond to variant CJD (vCJD) MM
(NHBY0/0014: in Figures 1B, 2–3, and S1), vCJD MM (NHBY0/
0003: in Figure 1C only), sporadic CJD (sCJD) MM (NHBX0/
0001), and sCJD MV (NHBX0/0004) strains with the indicated
reference codes and genotypes at polymorphic residue 129 [16]
(http://www.nibsc.ac.uk/spotlight/cjd/brainsamples.html). Nor-
mal BH was retrieved from the tissue bank of the Swiss National
Reference Centre of Prion Diseases (Zu ¨rich, Switzerland). All 10%
BHs (w/v) were homogenized in 0.25 M sucrose. Protein
concentrations were measured by BCA Assay (Pierce, Rockford,
IL) with most 10% BHs being ,10 mg/ml.
Antibodies
POM2, POM17, POM1, and POM19 mouse monoclonal
antibodies were obtained from the laboratory of Dr. Adriano
Aguzzi at the Institute of Pathology at the University Hospital of
Zu ¨rich. POM2 recognizes the sequence QPHGG(G/S)W whereas
POM17 and POM1 recognize the helix one region of PrP (,144–
155) and compete with 6H4 antibodies for binding [17,18].
POM19 recognizes residues 121–134 and 218–221 of the murine
PrP sequence, but does not recognize the human PrP sequence.
3F4 (Covance, Princeton, NJ) recognizes residues ,109–112
(MKHM) in the human PrP sequence. Anti-actin antibodies (clone
C4, Millipore, Billerica, MA) recognize residues ,50–70.
Western Blot Analysis
25 mg of normal and infectious BH (,2.5 ml of 10% BH) was
digested with 50 mg/ml of trypsin or Proteinase K (PK) in 0.56TBS
(25 mM Tris pH 7.5, 75 mM NaCl) with 0.5% Tween20, 0.5%
TritonX-100, and 5 mM CaCl2 for 1 hr at 37uC. Samples were
separated by 12% SDS-PAGE in parallel with 10 mg undigested
sample, and immunoblotted with anti-PrP antibodies (3F4, POM2,
POM17, or POM1) followed by an HRP-conjugated goat anti-
mouse polyclonal antibody(Pierce). Chemiluminescent imageswere
acquired via a Kodak Image Station 4000MM.
ELISA
10% BH was diluted 10-fold into TBS with 2% Sarkosyl (TBSS)
and digested with 0, 1, 10, or 100 mg/ml trypsin or PK for 1 hr at
37uC. Digestions were stopped by adding 2 mM PMSF and
Complete Mini protease inhibitor cocktail (Roche, Indianapolis,
IN) in four volumes of TBS. The samples were then detected by
direct ELISA. Briefly, approximately 500 nl of digested 10% BH
was centrifuged at 14,000 rpm for 30 minutes at 4uC. The PrP
Sc
pellets were denatured in 6M GdnSCN, diluted with an equal
volume of 0.1M NaHCO3 pH 8.9, and passively coated to ELISA
plates overnight. The plates were washed and blocked in 0.16
BlockerCasein in TBS (Pierce) and coated PrP was detected via
0.1 mg/ml 3F4, POM2 or POM17 antibodies and an alkaline
phosphatase (AP)-conjugated goat anti-mouse polyclonal antibody
(Pierce). Samples were analyzed by ELISA in triplicate and
washed six times with TBS 0.05% Tween20 between antibody
incubations. Finally, LumiphosPlus substrate (Lumigen, South-
field, MI) with 0.05% SDS was added to the wells and incubated
for 30 minutes at 37uC before the luminescence was measured via
a Luminoskan luminometer (Thermo Electron Corporation,
Waltham, MA).
Epitope Exposure of PrP
Sc
10% BH diluted 10-fold into TBSS was digested with 50 mg/ml
trypsin or PK for 1 hr at 37uC. Digestions were halted and
samples were centrifuged as described above. PrP
Sc pellets were
resuspended in 0.1M NaHCO3 pH 8.9, and passively coated to
ELISA plates overnight. The next day, coated proteins were
denatured with increasing concentrations of GdnHCl (0–5M) for
15 minutes at 37uC, and detected by direct ELISA using 0.5 mg/
ml 3F4 or 0.1 mg/ml POM2 antibodies as described above.
Immunoprecipitation of Native or Denatured PrP
Sc
10% BH diluted 10-fold into TBSS was digested with 50 mg/ml
trypsin, PK, ornothing for1 hr at 37uC. Digestions werehaltedand
samples were centrifuged as described above. PrP
Sc pellets were
then resuspended in 0 or 5M GdnHCl, and adjusted to a final
concentration of 0.1M GdnHCl in TBS with 1% TritonX-100 and
1% Tween20. PrP was subsequently immunoprecipitated with
POM2, 3F4, or POM17-conjugated to Protein G Dynal beads and
analyzed by POM1 immunoblot. (PrP
Sc from ,75 mg BH was
precipitated with,10 mg antibody.) POM19immunoprecipitations
served as a negative control as POM19 does not recognize human
PrP. Approximately 40% of an equivalent sample was loaded to
assess the input for each immunoprecipitation.
Supporting Information
Figure S1 Preservation of the octapeptide sequences allows
enhanced detection of PrP. Normal or vCJD BHs were digested
PrP
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(open circles) and detected by sandwich ELISA. Samples were
captured on 3F4-coated plates and detected with either alkaline
phosphatase-conjugated POM2 or POM17 antibody (RLU). The
signal contributed by PrPSc was estimated by subtracting Normal
BH-derived signal from vCJD BH-derived signal.
Found at: doi:10.1371/journal.pone.0009316.s001 (0.45 MB TIF)
Methods and Results S1
Found at: doi:10.1371/journal.pone.0009316.s002 (0.03 MB
DOC)
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